Justinus Kerners therapeutische Visionen “reloaded”

Zusammenfassung

In seiner zweiten großen “Wurstgift-Monographie” beschrieb Justinus Kerner 1822 mögliche Indikationen für eine Anwendung von Botulinumtoxin. Neben den mittlerweile etablierten Indikationen Bewegungsstörungen und vermehrte Drüsensekretion hielt er auch einen Einsatz zur Verbesserung der Wundheilung und bei psychiatrischen Erkrankungen für möglich. Die Übersicht soll zeigen, dass sich alle therapeutischen Visionen von Justinus Kerner erfüllt haben, wenngleich auch bei vielen der ungewöhnlichen Indikationen lediglich auf kasuistischer Basis.

Summary

In his second monograph on the so-called “Sausage Poison”, Justinus Kerner described in 1822 possible future indications for the treatment with botulinum toxin. Apart from the meanwhile established indications such as movement disorders and glandular hypersecretion, Kerner as well suggested the treatment of wounds and psychiatric diseases. The following review will demonstrate, that all of Kerner´s therapeutic visions have been realized, however in many of the uncommon indications by case reports only.

Schlüsselwörter

Botulinumtoxin - Justinus Kerner - Therapie - ungewöhnliche Indikationen

Keywords

Botulinum toxin - Justinus Kerner - therapy - uncommon indications

• Literatur

• 1 Al-Halfawy A, Gomaa NE, Refaat A. et al. Endobronchial injection of botulinum toxin for the reduction of bronchial hyperreactivity induced by methacholine inhalation in dogs. J Bronchology Interv Pulmonol 2012; 19: 277-283.
• 2 Aoki KR, Francis J, Jost WH. Mögliche antinozizeptive Mechanismen von Botulinumtoxin. Schmerz 2006; 20: 381-387.
• 3 Aurora SK, Winner P, Freeman MC. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011; 51: 1358-73.
• 4 Chuang YC, Kim DK, Chiang PH. et al. Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. BJU Int 2008; 102: 704-706.
• 5 Chuan-Jie Wu, Ya-Jun Lian, Ya-Ke Zheng. et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, doubleblind, placebo-controlled trial. Cephalalgia 2012; 32: 443-450.
• 6 Dabrowski E, Smathers SA, Ralstrom CS. et al. Botulinum toxin as a novel treatment for self-mutilation in Lesch-Nyhan syndrome. Dev Med Child Neurol 2005; 47: 636-639.
• 7 Eisenschenk S. et al. Botulinum toxin-induced paralysis of frontotemporal muscles improves seizure focus localization. Neurology 2002; 58: 246e9.
• 8 Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”. Neurology 1999; 53: 1850-1853.
• 9 Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg Am 2009; 34: 446-452.
• 10 Gassner HG, Brissett AE, Otley CC. et al. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006; 81: 1023-1028.
• 11 Gassner HG, Sherris DA, Friedman O. Botulinum toxin-induced immobilization of lower facial wounds. Arch Facial Plast Surg 2009; 11: 140-142.
• 12 Gazerani P. et al. Subcutaneous BoNT-A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009; 141: 60-69.
• 13 Gil RA, Hwynn N, Fabian T. et al. Botulinum toxin type A for the treatment of gastroparesis in Parkinson’s disease patients. Park Rel Disord 2011; 17: 285-287.
• 14 Grant AC. et al. Reduction of EEG myogenic artifact with botulinum toxin during video-EEG monitoring. Epilepsia 2007; 48: 324e9.
• 15 Gusek-Schneider GC, Erbguth F. Protektive Ptosis durch Botulinumtoxin-A-Injektion bei Hornhautaffektionen. Klin Monatsbl Augenheilkd 1998; 13: 15-22.
• 16 Hettrich CM, Rodeo SA, Hannafin JA. et al. The effect of muscle paralysis using Botox on the healing of tendon to bone in a rat model. J Shoulder Elbow Surg 2011; 20: 688-697.
• 17 Holzmann C, Dräger D, Mix E. et al. Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats. Behav Brain Res 2012; 234: 107-116.
• 18 Intiso D, Basciani M. Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury. J Rehabil Med 2009; 41: 1100-1102.
• 19 Jin L, Kollewe K, Krampfl K. et al. Treatment of phantom limb pain with botulinum toxin type A. Pain Med 2009; 10: 300-303.
• 20 Jost W, Kuhl A. Botulinum toxin: evidence-based medicine criteria in rare indications. J Neurol 2001; 248 (Suppl. 01) 39-44.
• 21 Jost W. Other indications of botulinum toxin therapy. Eur J Neurol 2006; 13 (Suppl. 01) 65-69.
• 22 Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Cotta: Stuttgart; 1822
• 23 Krämer H, Angerer C, Erbguth F. et al. BoNT A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003; 250: 188-193.
• 24 Kyrmizakis DE, Pangalos A, Papadakis CE. et al. The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J Oral Maxillofac Surg 2004; 62: 840-844.
• 25 Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: an evidence-based review. Int Dent J 2012; 62 (01) 1-5.
• 26 Matarasso SL. Treatment of facial chromhidrosis with botulinum toxin type A. J Am Acad Dermatol 2005; 52: 89-91.
• 27 Merté RL, Lanzl IM. Botulinumtoxin-Injektionen zur Erzeugung einer Ptosis. Ophthalmologe 2007; 104: 767-770.
• 28 Namazi H. Botulinum toxin type-A therapy in cluster headache: a novel molecular mechanism. J Headache Pain 2008; 09: 133.
• 29 Neundörfer B, Erbguth F, Kirchberger K, Majer M, Koelsch C, Hilz MJ. Botulinum toxin improves compensatory focal hyperhidrosis in Ross Syndrome. Clin Autonom Res 1998; 08: 288.
• 30 Olthoff A, Laskawi R. Zur oromandibulären, pharyngealen und laryngealen Anwendung von Botulinumtoxin. HNO 2012; 60: 475-478.
• 31 Ranoux D. et al. Botulinum Toxin Type A Induces Direct Analgesic Effects in Chronic Neuropathic Pain. Ann Neurol 2008; 64: 274-284.
• 32 Scolozzi P, Carrera E, Jaques B. et al. Successful treatment of a postpolio tinnitus with type a botulinum toxin. Laryngoscope 2005; 115: 1288-1290.
• 33 Sostak P, Krause P, Förderreuther S. et al. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain 2007; 08: 236-241.
• 34 Steffen A. Botulinumtoxin für die Behandlung sekretorischer Störungen im Kopf-Hals-Bereich. HNO 2012; 60: 484-489.
• 35 Tarsy D, Ro SI. Unusual position-sensitive jaw tremor responsive to botulinum toxin MD unusual position-sensitive jaw tremor responsive to botulinum toxin. Mov Disord 2006; 21: 277-278.
• 36 Teymoortash A, Müller F, Juricko J. et al. Botulinum toxin prevents radiotherapy-induced salivary gland damage. Oral Oncol 2009; 45: 737-739.
• 37 Trignano E, Dessy LA, Fallico N. et al. Treatment of pectoralis major flap myospasms with botulinum toxin type A in head and neck reconstruction. J Plast Reconstr Aesthet Surg 2012; 65: e23-28.
• 38 Winterhoff J, Laskawi R. Anwendung von Botulinumtoxin beim Blepharospasmus, Spasmus facialis und bei Synkinesien nach Fazialisdefektheilung. HNO 2012; 60: 479-483.
• 39 Wollmer MA, de Boer C, Kalak N. et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 2012; 46: 574-581.
• 40 Wu JM, Mamelak AJ, Nussbaum R. et al. Botulinum toxin a in the treatment of chromhidrosis. Dermatol Surg 2005; 31: 963-965.
• 41 Xiao L, Mackey S, Hui H. et al. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010; 11: 1827-1833.
• 42 Yuan RY. et al. Botulinum toxin for diabetic neuropathic pain. A randomized double-blind crossover trial. Neurology 2009; 72: 1-1.
• 43 Zabalza RJ. Sustained response to botulinum toxin in SUNCT syndrome. Cephalalgia 2012; 32: 869-872.